Coeptis Therapeutics, Inc.
NASDAQ:COEPBiotechnology
Healthcare
$14.64 +4.68%
+$0.73 today
- Market cap
- $57.63M
- Beta
- -0.43
- P/E (TTM)
- -8.3
- EPS (TTM)
- -$1.97
52W Low $6.80High $21.41
Volume 0.18M
Average 0.05M
Income Statement
Follow revenue through to earnings.
Revenue
$1.36M
FY 2025 · Annual
Operating Income
-$13.04M
FY 2025 · Annual
Net Income
-$11.92M
FY 2025 · Annual
Income Statement
USD
Metric | FY 2021 Dec 2021 | FY 2022 Dec 2022 | FY 2023 Dec 2023 | FY 2024 Dec 2024 | FY 2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 75K | 0 | 0 | 0 | 1.36M |
| Cost of Revenue | 0 | 0 | 0 | 0 | 180.63K |
| Gross Profit | 75K | 0 | 0 | 0 | 1.18M |
| Gross Margin | 100.0% | — | — | — | 86.7% |
| Research & Development | 0 | 20.89K | 6.67M | 2.33M | 1.28M |
| Selling, General & Admin | 14.12M | 34.18M | 13.82M | 6.72M | 11.95M |
| Operating Expenses | 14.12M | 34.2M | 21.49M | 10.05M | 14.23M |
| Depreciation & Amortization | 447.41K | 1M | 1.04M | 1.04M | 1.22M |
| EBITDA | (12.81M) | (36.35M) | (20.12M) | (9.38M) | (10.41M) |
| EBITDA Margin | -17086.3% | — | — | — | -763.9% |
| Operating Income | (14.05M) | (34.2M) | (21.49M) | (10.05M) | (13.04M) |
| Operating Margin | -18727.9% | — | — | — | -956.9% |
| Interest Income | 0 | 0 | 0 | 0 | 116.5K |
| Interest Expense | 187.13K | 218.41K | 107.69K | 396.12K | 642.38K |
| Other Income / Expenses | 596.65K | (3.38M) | 224.59K | (822.92K) | 766.31K |
| Income Before Tax | (13.45M) | (37.57M) | (21.27M) | (10.88M) | (12.28M) |
| Pre-Tax Margin | -17932.4% | — | — | — | -900.7% |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (13.45M) | (37.57M) | (21.27M) | (10.68M) | (11.92M) |
| Net Margin | -17932.4% | — | — | — | -874.3% |
| EPS (Basic) | (13.16) | (2.87) | (0.83) | (5.65) | (2.81) |
| EPS (Diluted) | (13.16) | (2.87) | (0.83) | (5.65) | (2.81) |
| 1.02M | 14.3M | 25.69M | 1.93M | 4.23M | |
| 1.02M | 14.3M | 25.69M | 1.93M | 4.23M |
COEP Earnings Waterfall · TTM
NASDAQ:COEP · Revenue to Net Income
Key Ratios
EPS$-2.47
Gross Margin78.4%
Net Margin-1658.1%
P/E Ratio-5.8
P/S Ratio289.5
Analysis
$1.4M of revenue converted into -$11.9M of net income for the selected period. Gross margin is 78.4% and net margin is -1658.1%, showing how much revenue survives after costs and taxes. EPS is $-2.47, tying the income statement back to per-share earnings.
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 424B3 | 424B3 filing | Jun 18, 2026 | |
| EFFECT | EFFECT filing | Jun 16, 2026 | |
| POS AM | POS AM filing | Jun 16, 2026 | |
| S-1 | S-1 filing | Jun 9, 2026 | |
| 4 | Statement of changes in beneficial ownership | Jun 8, 2026 |
How much revenue does COEP generate?
Coeptis Therapeutics, Inc. (COEP) reported $1.36M of revenue in fiscal 2025.
Is COEP profitable?
Coeptis Therapeutics, Inc. (COEP) reported -$11.92M of net income, with a net margin of -874.3%.
Continue the stock analysis
Jump to another research area for this company.